In an interview with Targeted Oncology, Sarbajit Mukherjee, MD, gastrointestinal (GI) medical oncologist at Baptist Health ...
Median overall survival differed significantly by race: 36.8 months for Black patients versus 48.4 months for White patients ...
Nonresponse to bridging therapy and high lymphocyte count were predictive of parkinsonism and nonrelapse mortality (NRM) after treatment with ciltacabtagene autoleucel (cilta-cel; Carvykti) in ...
The FDA has expanded the approval of Hologic’s Aptima human papillomavirus (HPV) assay for clinician-collected primary ...
In patients with metastatic breast cancer (mBC) who progress after first-line treatment of CDK4/6 and aromatase inhibitors ...
In an interview with Targeted Oncology, Sarbajit Mukherjee, MD, GI medical oncologist at Baptist Health Miami Cancer ...
The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted ...
A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...
The FDA has granted fast track designation to the investigational oncolytic virus immunotherapy pelareorep (Reolysin) in combination with bevacizumab (Avastin) and FOLFIRI (leucovorin, fluorouracil, ...
During a live event, Sumanta K. Pal and other oncologists discuss the safety and efficacy of belzutifan for advanced renal ...
The sBLA is supported by results from the pivotal phase 3 TROPION-Breast02 clinical trial (NCT05374512), which evaluated the ...
A new drug application (NDA) and a biologics license application (BLA) have been resubmitted and accepted by the FDA for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results